Esperion Therape Stock Price, News & Analysis

Esperion (NASDAQ: ESPR) has announced a virtual key opinion leader (KOL) event scheduled for January 22, 2025, at 11:30 a.m. ET. The event will focus on the real-world use of NEXLETOL® and NEXLIZET®, featuring discussions led by LeAnne Bloedon, VP of Clinical Development, and Dr. Patrick Moriarty from The University of Kansas Medical Center.

The webinar will address unmet needs in LDL-Cholesterol management for cardiovascular disease prevention. Esperion's medications are FDA-approved, oral, once-daily, non-statin medicines supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients.

The company is also advancing its next-generation program developing ATP citrate lyase inhibitors (ACLYi), focusing on creating highly potent and specific inhibitors with allosteric mechanisms. The event will be accessible via webcast on Esperion's website, with replay available for approximately 90 days.

Esperion (NASDAQ: ESPR) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for Wednesday, January 15, 2025, at 3:45 p.m. PT. The presentation will be accessible via webcast through Esperion's investor and media section, with replay available for approximately 90 days.

Esperion is a commercial stage biopharmaceutical company that has developed the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. These medications are backed by the CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients.

The company is advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi), leveraging new structural and functional insights for developing highly potent and specific inhibitors with allosteric mechanisms. Esperion aims to expand globally through commercial execution, international partnerships, and pre-clinical pipeline advancement.

Esperion (NASDAQ: ESPR) has completed significant refinancing transactions to strengthen its balance sheet. The company secured a $150 million senior secured term loan facility led by Athyrium Capital Management and HealthCare Royalty, along with issuing $100 million in new convertible notes. These funds will be used to repay $210 million of existing $265 million convertible debt, with $40 million allocated as operating cash.

The new loan bears interest at 9.75% for cash payments or 11.75% if paid in-kind. The new convertible notes mature on June 15, 2030, with a 5.75% annual interest rate and an initial conversion price of $3.06 per share. This restructuring affects 80% of Esperion's existing debt, extending maturity dates by five years or more.

Esperion (NASDAQ: ESPR) has announced a $210 million convertible debt financing through privately negotiated agreements. The company will issue $100 million of 5.75% Convertible Senior Subordinated Notes due 2030, consisting of $57.5 million in new notes plus $153.4 million in cash to exchange $210.1 million of existing 2025 Notes, and $42.5 million in new notes for cash.

The new notes will mature on June 15, 2030, with a 5.75% annual interest rate paid semi-annually. The initial conversion rate is 326.7974 shares per $1,000 principal amount, representing a conversion price of approximately $3.06 per share. The Exchange Transactions will be partially funded through a new $150 Million Senior Secured Term Loan with Athyrium Capital Management.

Esperion Therapeutics (NASDAQ: ESPR) has entered into a licensing agreement with Neopharm Israel for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Israel. The agreement includes an upfront payment, near-term milestone payments, and tiered royalties on product sales.

Under the agreement terms, Neopharm will receive exclusive commercialization rights in Israel, Gaza, and West Bank. Esperion will receive a one-time upfront cash payment within 30 days of signing, plus an additional payment following marketing approval and inclusion in the National Healthcare Reimbursement Basket. The partnership aims to address cardiovascular disease, which remains a leading cause of death globally.

Esperion (NASDAQ: ESPR) has submitted New Drug Submissions (NDSs) to Health Canada for NEXLETOL and NEXLIZET, once-daily oral non-statin medications for reducing LDL cholesterol and cardiovascular risk. These treatments target adults unable to take recommended statin therapy, with either established cardiovascular disease or high risk for CVD events. According to Canadian health data, approximately 2.6 million Canadian adults live with diagnosed heart disease, with 14 adults dying every hour from the condition.

Esperion (NASDAQ: ESPR) announced that Otsuka Pharmaceutical has submitted a New Drug Application in Japan for bempedoic acid to treat hypercholesterolemia. The Japanese Phase 3 trial, involving 96 patients, demonstrated significant efficacy with a -25.25% change in LDL-C levels compared to -3.46% in the placebo group after 12 weeks. The drug showed consistent safety profile with previous trials and no serious adverse events. This treatment targets patients who have insufficient response to statins or cannot tolerate them. Bempedoic acid works by inhibiting ATP citrate lyase in the liver's cholesterol synthesis pathway and is already marketed in the US and Europe.

Esperion (NASDAQ: ESPR) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference scheduled for Thursday, December 5, 2024, at 12:30 p.m. ET. The event will be webcasted and accessible through Esperion's investor and media section website, with replay available approximately two hours after completion and archived for 90 days.

Esperion focuses on developing innovative medicines for cardiovascular and cardiometabolic diseases, particularly targeting high cholesterol. The company aims to support healthcare providers in reducing LDL-cholesterol levels effectively, addressing the needs of millions of patients whose health requirements are not met by current standards.

Esperion (ESPR) presented new exploratory data from the CLEAR Outcomes trial at the 2024 AHA Scientific Sessions, highlighting significant benefits of NEXLETOL (bempedoic acid). The analysis showed patients with Peripheral Artery Disease (PAD) taking bempedoic acid were 36% less likely to experience major adverse limb events compared to placebo. Additional data revealed that after 3 months, 67% of patients using bempedoic acid and ezetimibe combination achieved LDL-C levels below 100 mg/dL, with 55% maintaining these levels at 12 months.